| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 152.33▲ | 151.80▲ | 151.42▲ | 136.89▲ | 128.30▲ |
| MA10 | 152.14▲ | 150.80▲ | 146.00▲ | 127.46▲ | 108.28▲ |
| MA20 | 151.64▲ | 144.02▲ | 137.29▲ | 119.93▲ | 87.51▲ |
| MA50 | 150.95▲ | 134.83▲ | 127.83▲ | 97.50▲ | 71.20▲ |
| MA100 | 145.34▲ | 127.22▲ | 121.30▲ | 81.59▲ | 61.05▲ |
| MA200 | 136.99▲ | 120.17▲ | 110.72▲ | 71.53▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.128▲ | 0.421▲ | 1.729▲ | 2.127▲ | 7.362▲ |
| RSI | 61.157▲ | 72.994▲ | 74.881▲ | 74.444▲ | 92.082▲ |
| STOCH | 59.118 | 83.465▲ | 88.103▲ | 75.576 | 92.752▲ |
| WILL %R | -5.000▲ | -1.833▲ | -1.609▲ | -0.798▲ | -0.452▲ |
| CCI | 136.570▲ | 89.914 | 94.029 | 179.008▲ | 154.547▲ |
| ▲ RSI | $BLTE RSI(14) Crossed Above 70 | Set Alert |
| ▲ GAP | $BLTE Open Gap Up %5 | Set Alert |
| ▲ GAP | $BLTE Open Gap Up %3 | Set Alert |
| ▲ GAP | $BLTE Open Gap Up %2 | Set Alert |
| ▲ BREAK | $BLTE Price Breaks 60 Days High | Set Alert |
| ▲ BREAK | $BLTE Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $BLTE Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $BLTE Price Breaks 10 Days High | Set Alert |
| CDL | $BLTE Hanging Man Candlestick Pattern Detected | Set Alert |
| CDL | $BLTE Doji Star Candlestick Pattern Detected | Set Alert |
| CDL | $BLTE Doji Candlestick Pattern Detected | Set Alert |
|
Monday, December 01, 2025 05:33 AM
Investing.com -- Belite Bio Inc ADR (NASDAQ:BLTE) stock jumped 17.1% in premarket trading Monday after announcing positive Phase 3 trial results for Tinlarebant, marking the first successful pivotal ...
|
|
Monday, December 01, 2025 05:14 AM
Belite Bio's Tinlarebant cut lesion growth in a pivotal Stargardt Phase 3 trial, showing strong efficacy and a consistent safety profile.
|
|
Monday, December 01, 2025 03:10 AM
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/12/25 | 153.995 | 153.995 | 131.35 | 153.58 | 740,795 |
| 28/11/25 | 130.00 | 138.105 | 129.00 | 137.44 | 75,294 |
| 26/11/25 | 130.00 | 133.00 | 122.75 | 129.62 | 118,338 |
| 25/11/25 | 140.75 | 141.00 | 115.41 | 127.80 | 537,901 |
| 24/11/25 | 126.50 | 144.99 | 126.00 | 136.00 | 285,672 |
| 21/11/25 | 110.08 | 121.89 | 108.00 | 120.56 | 363,909 |
| 20/11/25 | 119.22 | 120.28 | 105.88 | 109.18 | 146,491 |
| 19/11/25 | 123.50 | 124.00 | 119.0001 | 120.365 | 59,259 |
| 18/11/25 | 116.00 | 125.24 | 116.00 | 123.19 | 136,197 |
| 17/11/25 | 116.90 | 120.9739 | 116.29 | 116.91 | 52,656 |
|
|
||||
|
|
||||
|
|